Drug Type Oncolytic virus |
Synonyms OH2 Oncolytic Viral Therapy, rHSV2hGM-CSF, BS 001 + [5] |
Target |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Unresectable Melanoma | Phase 3 | CN | 08 Mar 2023 | |
Melanoma | Phase 3 | CN | 23 Feb 2023 | |
Biliary Tract Neoplasms | Phase 2 | CN | 18 Oct 2023 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | CN | 17 Oct 2023 | |
Colorectal Cancer | Phase 2 | CN | 17 Oct 2023 | |
Colorectal Liver Metastases | Phase 2 | CN | 20 Oct 2022 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 2 | CN | 11 Jul 2022 | |
Bladder Cancer | Phase 2 | CN | 25 May 2022 | |
Locally Advanced Bladder Carcinoma | Phase 2 | CN | 23 May 2022 | |
Metastatic Neoplasm to the Bladder | Phase 2 | CN | 23 May 2022 |
Phase 2 | 26 | OH2 monotherapy | qscaeaaqxa(byalrodrgc) = eaqwzvumbf eissulsezg (lcdllszuhi ) View more | Positive | 24 May 2024 | ||
qscaeaaqxa(byalrodrgc) = bvoftlgisl eissulsezg (lcdllszuhi ) View more | |||||||
Phase 1 | - | gfgbqhepau(xfrqpnxqut) = fdwhjxikhg bxabrimkco (dkcsxoqihm ) | Positive | 06 Nov 2022 | |||
(接受PD-1治疗失败且疾病分期为III-IVM1a的亚组人群) | gfgbqhepau(xfrqpnxqut) = lqaoftlusq bxabrimkco (dkcsxoqihm ) | ||||||
NCT04386967 (ASCO2022) Manual | Phase 1 | 35 | fainyujnpp(qfdzywyphv) = cqcmjzvxux xqneadumve (cniwctbpyl ) View more | Positive | 02 Jun 2022 |